The EPS beat and completed enrollment are modest positives, but the stock remains a binary event-driven play on the Q1 2027 NDA submission and potential FDA approval. Monitor for any updates on the PYNNACLE Phase 2 data or regulatory interactions that could accelerate or delay the timeline.
Price Chart
Executive Summary
PMV Pharma reported Q2 2026 results with a net loss of $18.1M ($-0.34/share), beating consensus estimates of $-0.38. The company completed enrollment of the primary analysis cohort for rezatapopt in platinum-resistant/refractory ovarian cancer and reiterated its NDA submission timeline for Q1 2027. Cash runway extends through Q2 2027, but the pre-revenue clinical-stage biotech continues to burn cash with no near-term revenue catalyst.
Key Financial Metrics
Key Facts
- Net loss of $18.1M for Q2 2026 vs $21.2M in Q2 2025, a 14.6% improvement
- EPS of $-0.34 beat consensus estimate of $-0.38 (10.5% beat)
- Cash, cash equivalents, and marketable securities of $79.4M as of June 30, 2026, down from $112.9M at Dec 31, 2025
- Enrollment of platinum-resistant/refractory ovarian cancer patients for primary analysis in Phase 2 PYNNACLE trial completed
- NDA submission for rezatapopt in platinum-resistant/refractory ovarian cancer planned for Q1 2027
- R&D expenses decreased to $14.7M from $18.4M year-over-year
- Cash runway expected through Q2 2027
Financial Impact
Net loss improved by $3.1M year-over-year; cash burn of $34.3M in first half of 2026 vs $36.6M in first half of 2025
Risk Factors
- Clinical trial failure or regulatory rejection of rezatapopt NDA
- Cash runway only through Q2 2027, requiring future financing
- No approved products or revenue streams
- Competition from other p53-targeting therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-350445 |
| Document: pmvp-20260814.htm | 0001193125-26-350445 |
| Document: 0001193125-26-350445-index-headers.html | 0001193125-26-350445 |
| Document: 0001193125-26-350445-index.html | 0001193125-26-350445 |
| Document: 0001193125-26-350445.txt | 0001193125-26-350445 |
| 8-K Data (Synthetic) | 0001193125-26-350445 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 8-K | $1.78 | awaiting T+20 | — | $1.13 (−36.52%) |
Aug 31, 2026 8w ago | Press Release | $1.29 $1.67 | ▼ −29.46% | ▼ −29.14% | $1.13 (+12.40%) |
Aug 31, 2026 8w ago | 8-K | $1.29 $1.67 | ▲ +29.46% | ▲ +29.14% | $1.13 (−12.40%) |
Aug 31, 2026 8w ago | Press Release | $1.29 $1.67 | ▼ −29.46% | ▼ −29.14% | $1.13 (+12.40%) |
Aug 31, 2026 8w ago | Press Release | $1.29 $1.67 | ▲ +29.46% | ▲ +29.14% | $1.13 (−12.40%) |
Aug 14, 2026 10w ago | 8-K | $1.26 $1.46 | ▲ +15.87% | ▲ +17.86% | $1.13 (−10.32%) |
Aug 14, 2026 10w ago | Press Release | $1.26 $1.46 | ▲ +15.87% | ▲ +17.86% | $1.13 (−10.32%) |
May 12, 2026 23w ago | 8-K | $1.42 $1.06 | ▼ −25.35% | ▼ −23.62% | $1.13 (−20.42%) |
May 12, 2026 23w ago | Press Release | $1.42 $1.06 | ▼ −25.35% | ▼ −23.62% | $1.13 (−20.42%) |
Apr 22, 2026 26w ago | DEFA14A | $1.48 $1.31 | ▼ −11.49% | ▼ −14.65% | $1.13 (−23.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers